Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®*, its Third Approved Biosimilar in the U.S.
Tyenne® is the first tocilizumab biosimilar by Fresenius Kabi, an operating company of Fresenius, with an intravenous an…
Tyenne® is the first tocilizumab biosimilar by Fresenius Kabi, an operating company of Fresenius, with an intravenous an…
Subcutaneous administration of oncology drugs with digital therapy support Integrating Gx SensAir drug delivery device w…
Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidia…
Attgeno AB today announces a research collaboration targeting to explore Supernitro (PDNO) as a new potential treatment…
The consistently expanding medical industry, introduction of newer medical treatments and products, and growing overall…
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced…
First-ever data on therapeutic miR-132 inhibition in a large animal model of nonischemic heart failure with cardiac hype…
. - Einreichung in den USA für Patienten mit rezidivierenden indolenten B-Zell-Non-Hodgkin-Lymphomen (iNHL) - In der EU…
MerLion Pharmaceuticals GmbH (MerLion), a biopharmaceutical company focused on research and development of novel antibio…
Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) base…